Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Radiooncology / Radiobiology

Prof. Dr. med. Dr. h. c. Michael Baumann

The division of RadioOncology/ RadioBiology works on the translational aspect of integrating radiobiological findings into clinical patient outcome parameters and clinical studies. To follow the translational concept "from bench-to-bedside" in both directions, we are also working on reverse translation bringing clinical findings back to the lab bench in order to unravel the biological mechanisms behind radiotherapy and combined radiotherapy treatments. Both directions of the translational chain require the efforts of a multidisciplinary team of clinician scientists, bioinformaticians, biologists, and biostatisticians and their close interactions. Our research ranges from basic biology over biostatistics and pre-clinical trials to medical informatics, including image processing, and assistance and support of clinical studies.

In close collaboration with our partners here at the DKFZ, the clinic and site-overarching with the German Cancer Consortium (DKTK), our current projects include:

  • Elucidation of molecular mechanisms of radioresistance in tumor models with special emphasis on the hypoxic micromilieu in tumors and the investigation of inter- and intratumoral heterogeneity on single cell level
  • Biomarker validation and drug screens in preclinical set-ups of 3D in vitro cultures and mouse models
  • Clinical study design, management and monitoring

The knowledge generated (not only) with our research will be translated into the conception of clinical trials for personalized treatments. Future clinical trials and anti-tumor therapies won´t rely on a single treatment modality but rather on combinatorial therapies customized to the patient’s individual known clinical and biological profile. New insight into the molecular biological mechanisms of radioresistance and tumor heterogeneity will help to establish intracellular signaling pathways involved in therapy failure and thereby elucidate potential drugable targets in combination with radiotherapy. Patients' individual imaging parameters will be used to compare and integrate them with the corresponding clinical and biological information in order to further stratify each patient for the most effective and least aggressive therapy.


Prof. Dr. med. Dr. h. c. Michael Baumann
Radiooncology / Radiobiology (E220)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 2851

Selected Publications

  • Baumann M, Ebert N, Kurth I, Bacchus C, Overgaard (2020) What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. J. Mol Oncol. 2020 Jul;14(7):1577-1585.
  • Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova I, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, Schwager C, Dowle A, Hein L, Kunz-Schughart L, Abdollahi A, Lohaus F, Krause M, Baumann M, Linge A, Dubrovska A (2019) The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity. Clin Cancer Res 25(10):3152-3163
  • Baumann M, et al.: Radiation oncology in the era of precision medicine. Nat Rev Cancer.16(4) (2016), 234-49.
  • Kurth I, et al.: Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget (2015) 6: 34494-34509
to top
powered by webEdition CMS